Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-A01833-36 | Other Identifier | ID-RCB |
Not provided
Not provided
Authorization denied by Ethical Comitee
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Institut Pasteur | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The investigators performed in April 2020, a screening campaign of asymptomatic staff working in elderly nursing homes in Paris France (EHPAD), where the virus had been circulating actively in March and April 2020. Among 241 employees tested in four nursing homes, 32 (13.2%) were asymptomatic carriers of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2).
Few data are available concerning the humoral immune response of asymptomatic carriers, the elicitation and duration of neutralizing antibodies and the duration of protection.
The purpose of the study is to determine whether these asymptomatic persons develop a humoral immune response, whether this immune response is durable and whether it is protective against the risk of reinfection
The investigators performed in April 2020, a screening campaign of asymptomatic staff working in elderly nursing homes in Paris, France, where the virus had been circulating actively in March and April 2020. Among 241 employees tested in four nursing homes, 32 (13.2%) were asymptomatic carriers of SARS-Cov-2.
Few data are available concerning the humoral immune response of asymptomatic carriers, the elicitation and duration of neutralizing antibodies and the duration of protection.
The main objective of this study is to describe the SARS-Cov-2 asymptomatic employees with positive immunoglobulin G (igG) serology at month 1-2 post infection.
Secondary objectives are
The design will be a case control study between
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cases | Other | SARS-Cov-2 asymptomatic nursing homes employees |
|
| Controls | Other | cohort of patients with a symptomatic COVID-19, preferably recruited in nursing homes or in case of difficulties in the virology service of COCHIN Hospital. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| serology | Other | serology at M3 and serology at M6 |
|
| Measure | Description | Time Frame |
|---|---|---|
| rate of positive IgG serology | positive IgG (Immunoglobulin G) SARS-Cov-2 serology after infection of asymptomatic employees | month 1-2 post infection |
| Measure | Description | Time Frame |
|---|---|---|
| rate of positive IgG serology | positive IgG (Immunoglobulin G) SARS-Cov-2 serology after infection of asymptomatic employees | month 3-6 post infection |
| rate of positive immunoglobulin M (IgM) serology |
Not provided
Common inclusion criteria:
Inclusion Criteria for Cases (asymptomatic COVID-19 patients) :
Inclusion criteria for controls (symptomatic COVID-19 patients) :
COVID-19 symptoms defined by:
It is part of the database of the virology department of Cochin Hospital (in case of failure to recruit health care workers in the EHPADs).
*Exclusion criteria :
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dominique Salmon, MD, PhD | Assistance Publique - Hôpitaux de Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| HOTEL DIEU Hospital | Paris | 75004 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Case control longitudinal study, Interventional minimal risk study
Not provided
Not provided
Not provided
Not provided
positive IgM SARS-Cov-2 serology after infection of asymptomatic employees
| month 1-2-3 and 6 post infection |
| rate of neutralizing antibodies | concentration of neutralizing antibodies | month 1-2-3 and 6 post infection |
| questionnaire | Associated factors with the presence of antibodies | month 1-2-3 and 6 post infection |
| re infection | of asymptomatic patients with SARS-Cov-2 | through study completion, an average of 8 months |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |